Your browser is no longer supported. Please, upgrade your browser.
CAPR [NASD]
Capricor Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own2.24% Shs Outstand22.86M Perf Week-0.50%
Market Cap95.79M Forward P/E- EPS next Y-0.95 Insider Trans0.00% Shs Float22.51M Perf Month-15.57%
Income-18.00M PEG- EPS next Q-0.22 Inst Own10.20% Short Float5.21% Perf Quarter-20.48%
Sales0.30M P/S319.31 EPS this Y57.40% Inst Trans-32.09% Short Ratio1.73 Perf Half Y0.25%
Book/sh1.46 P/B2.71 EPS next Y-5.60% ROA-46.60% Target Price- Perf Year-14.47%
Cash/sh- P/C- EPS next 5Y- ROE-56.10% 52W Range3.13 - 8.40 Perf YTD15.45%
Dividend- P/FCF- EPS past 5Y35.90% ROI-43.10% 52W High-52.02% Beta6.44
Dividend %- Quick Ratio12.20 Sales past 5Y-43.80% Gross Margin- 52W Low28.75% ATR0.28
Employees26 Current Ratio12.20 Sales Q/Q309.30% Oper. Margin- RSI (14)46.48 Volatility4.32% 6.69%
OptionableYes Debt/Eq0.10 EPS Q/Q9.80% Profit Margin- Rel Volume0.15 Prev Close3.96
ShortableYes LT Debt/Eq0.10 EarningsAug 12 AMC Payout- Avg Volume677.16K Price4.03
Recom2.00 SMA20-2.43% SMA50-7.12% SMA200-15.76% Volume101,348 Change1.77%
Dec-26-18Downgrade Maxim Group Buy → Hold
Jan-26-18Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17Resumed Rodman & Renshaw Buy $14
Jul-06-16Resumed H.C. Wainwright Buy $13
Jun-15-16Initiated ROTH Capital Buy
Sep-24-21 09:28AM  
07:00AM  
Sep-22-21 04:05PM  
Sep-07-21 09:00AM  
Sep-02-21 08:30AM  
Aug-19-21 09:45AM  
Aug-12-21 04:01PM  
Aug-05-21 09:00AM  
Jul-27-21 08:00AM  
Jun-23-21 08:27AM  
Jun-17-21 09:00AM  
Jun-13-21 02:37PM  
Jun-10-21 09:15AM  
May-18-21 08:30AM  
May-13-21 04:05PM  
02:30PM  
May-12-21 09:00AM  
May-06-21 08:30AM  
Apr-29-21 08:00AM  
Mar-13-21 01:28AM  
Mar-11-21 04:01PM  
02:30PM  
Mar-09-21 09:15AM  
Mar-04-21 09:00AM  
Feb-01-21 09:15AM  
Jan-19-21 09:15AM  
Jan-12-21 09:05AM  
Dec-29-20 09:15AM  
Nov-24-20 07:30AM  
Nov-12-20 04:01PM  
02:30PM  
Nov-09-20 09:15AM  
Nov-05-20 09:00AM  
Sep-23-20 09:25AM  
Sep-10-20 09:15AM  
Sep-01-20 04:34PM  
Aug-31-20 09:00AM  
Aug-25-20 11:34AM  
09:15AM  
Aug-06-20 04:01PM  
Jul-30-20 09:15AM  
Jul-28-20 12:33PM  
Jul-23-20 07:28AM  
Jun-04-20 09:15AM  
May-29-20 01:08PM  
May-26-20 09:25AM  
May-14-20 05:35PM  
04:01PM  
May-13-20 04:30PM  
07:00AM  
May-06-20 06:44PM  
Apr-30-20 12:23AM  
Apr-29-20 09:15AM  
Apr-24-20 07:31AM  
Apr-13-20 09:00AM  
Apr-06-20 04:02PM  
Apr-03-20 08:00AM  
Mar-24-20 08:00AM  
Mar-19-20 08:30AM  
Mar-18-20 04:01PM  
02:30PM  
Mar-17-20 08:00AM  
Mar-11-20 04:30PM  
Mar-10-20 07:01AM  
Feb-13-20 11:30AM  
Feb-07-20 04:12PM  
Feb-03-20 07:39AM  
Jan-28-20 07:01AM  
Dec-19-19 01:14PM  
Dec-17-19 01:52PM  
Dec-11-19 05:29AM  
Nov-07-19 05:15PM  
04:00PM  
Nov-01-19 09:00AM  
Oct-27-19 09:16AM  
Oct-21-19 09:25AM  
Oct-14-19 09:35AM  
Oct-07-19 12:27PM  
06:30AM  
Oct-04-19 10:09AM  
Oct-02-19 09:15AM  
Oct-01-19 09:14AM  
Sep-26-19 11:24AM  
09:47AM  
Sep-25-19 08:44AM  
Sep-24-19 11:25AM  
09:20AM  
07:42AM  
07:30AM  
Sep-23-19 09:44AM  
Sep-21-19 08:20AM  
Sep-20-19 09:12AM  
Sep-19-19 08:41AM  
Sep-17-19 12:29PM  
08:38AM  
07:00AM  
Sep-11-19 09:04AM  
Sep-06-19 07:30AM  
Aug-23-19 08:37AM  
Aug-22-19 07:31AM  
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.